

ΛΕΙΤΟΥΡΓΙΚΕΣ ΔΟΚΙΜΑΣΙΕΣ ΣΤΟ ΑΙΜΟΔΥΝΑΜΙΚΟ ΕΡΓΑΣΤΗΡΙΟ

ΡΑΜΜΟΣ ΑΗΔΟΝΗΣ

ΚΑΡΔΙΟΛΟΓΟΣ




Β' ΚΑΡΔΙΟΛΟΓΙΚΗ ΚΛΙΝΙΚΗ

Π.Γ.Ν.Ι.


- Στεφανιογραφία (coronary angiography) => ***gold standard*** στην εκτίμηση Στεφανιαίας Νόσου

- Διαγνωστικό Πρόβλημα:

- Ενδιάμεσες βλάβες (40-70%)
- Έκκεντρες βλάβες
- Διάχυτες στενώσεις



- Πολύ συχνά
 - Σύμπτωμα (στηθάγχη) => Χωρίς αγγειογραφικά κριτική στένωση
 - Μικροαγγειακή ή
 - Ενδοθηλιακή Δυσλειτουργία



Δομή και Φυσιολογία Στεφανιαίων Αγγείων

Στεφανιαία Κυκλοφορία: 3 τμήματα

❑ Μεγάλες επικαρδιακές στεφανιαίες αρτηρίες

- Μέγεθος > 500μm
- <10% της συνολικής αντίστασης
- Η ΑΠ παραμένει σταθερή στα αγγεία αυτά


❑ Εξωκαρδιακά Περιαρτηρίδια


- 100-500μm

❑ Τριχοειδή αγγεία




90% των αντιστάσεων
(μικροκυκλοφορία)





The sigmoid line shows resting coronary blood flow which has an autoregulated range at physiological pressure. Following metabolic demands the coronary circulation undergoes vasodilatation which when maximal becomes a pressure driven system (the oblique straight line). The difference between the two lines is the coronary flow reserve which is a variable parameter depending on the perfusion pressure.



- (A) Coronary flow reserve is fixed and an increase in metabolic demand causes ischaemia when not accommodated by the coronary flow reserve.
- (B) Coronary flow reserve is variable because of microvascular influences and now a lesser amount of myocardial demand also produces ischaemia.

- Μέγιστη διάθεση O_2 στα στεφανιαία αγγεία:
Ηρεμία
- Αύξηση αναγκών $O_2 \Rightarrow$ Αύξηση ροής
- Τμήμα 1 & 2 σε φυσιολογικές συνθήκες
επιτυγχάνουν διάταση μέσω ρύθμισης ροής
- Όταν υπάρχει στένωση σε στεφανιαίο αγγείο \Rightarrow
πτώση πίεσης στο άπω τμήμα
- Τμήμα 2 \Rightarrow αγγειοδιαστολή


Φάρμακα για ΥΠΕΡΑΙΜΙΑ

Table 1 Substances used in the catheterization laboratory for coronary vascular function assessment

| Substance | Doses | Site of action | Endothelium response | Effect |
|---------------|---|-------------------------|----------------------|---|
| Adenosine | Iv: 140 µg/kg per minute Ic: 20-150 µg bolus | Microvascular | Independent | Direct vasodilation |
| Acetylcholine | Ic: 10^{-6} M/ 10^{-5} M/ 10^{-4} M | Micro and macrovascular | Dependent | Vasodilation if normal endothelial function; vasoconstriction if endothelial dysfunction |
| Nitroglycerin | Ic: 200 µg bolus | Macrovascular | Independent | Vasodilation |
| Nitroprusside | Ic 0.3-0.9 µg/kg bolus | Micro and macrovascular | Independent | Vasodilation |
| Papaverine | Ic: 8-20 mg bolus | Micro and macrovascular | Independent | Enzyme Phosphodiesterase inhibition Vasodilation |
| Regadenoson | Iv: 400 µg bolus | Microvascular | Independent | Adenosine receptor agonist vasodilation |

Four Types of Adenosine Receptors

- A1 – AV Block
- A2A – Vasodilate small coronary vessels
- A2B – Mast cell degranulation
- A3 - Bronchoconstriction



ΑΔΕΝΟΣΙΝΗ

- Παράγεται από αγγειακούς λείους μύες και ενδοθηλιακά κύτταρα
- Αγγειοδιαστολή: Σύνδεση με A2a
- A1, A3 και A2β υποδοχείς
 - **Βρογχόσπασμος**
 - **AV Nodal Blockade**
- Πλεονέκτημα: Πολύ μικρός χρόνος ημίσειας ζωής (2-10 sec)
- Ενδοστεφανιαία χορήγηση
- Χρειάζεται μετά αμινοφυλλίνη

Intracoronary adenosine


- Intracoronary adenosine is an extremely safe agent to induce maximal hyperaemia due to short half time – repeated doses.
- Peak effect occurs less than 10 sec after administration but has a duration of action of less than 20 sec
 - RCA: 40 µg
 - LCA: 60 µg
- This should be increased in 20–30 mcg increments to a maximum of 150 µg if FFR between 0.75 and 0.80
- Main side effect is short lasting, transient AV-block, most frequently noted after administration of the drug into the right coronary artery

IC adenosine >100 μ g (up to 150 μ g to 200 μ g)




IC Adenosine 150 μ g

82 pts/108 stenoses




50 pts/50 stenoses



www.cardio-aalst.be

Intracoronary Adenosine preparation

- **Nitrates** prior to measurement – to avoid spasm.



- Guide catheter
 - **Without side-holes**
 - **Coaxial engagement**

- Setup of the machine. **Beat-to-beat basis** rather than from a mean. Mean readings are likely to result in an underestimation of the maximum gradient
- Make sure **to interrupt the AO pressure** for as short as possible

IC Preparation

1 amp = 1 ml = 5 mg (Item)

Add: 5 mg adenosine (1 ml)
To: 250 ml NaCl

20 µg/ml



5 milligrams of adenosine can be added to 250ml NaCl to produce 20µg/ml



RCA: (40 µg/ml) = 2 ml (20 µg/ml)
LCA: (60 µg/ml) = 3 ml (20 µg/ml)

OR

1 amp = 2 ml = 6 mg (Sanofi)

Add: 5 mg adenosine (1.7 ml)
To: 500 ml NaCl

10 µg/ml



5 milligrams of adenosine can be added to 500ml NaCl to produce 10µg/ml



RCA: (40 µg/ml) = 4 ml (10 µg/ml).
LCA: (60 µg/ml) = 6 ml (10 µg/ml).

1) Gilles Rioufol, et al.
150 microgram intracoronary adenosine bolus for accurate fractional flow reserve assessment in angiographically intermediate coronary stenosis.
EuroIntervent. 2005;2:204-207.

2) R Lopez Palop
Adequate Intracoronary Adenosine Doses to Achieve Maximum Hyperaemia in Coronary Functional Studies by Pressure Derived Fractional Flow Reserve: A Dose Response Study
Heart. 2004;90:95-96.

3) Gianni Castella
Are high doses of intracoronary adenosine an alternative to standard intravenous adenosine for the assessment of fractional flow reserve?
Am Heart J 2004;148:590-5.

4) N Pijls and B De Bruyne
Coronary Pressure 2nd Edition
Kluwer Academic Publishers

5) Clinical practice at the Coronary Intervention Department, Stockholm South Hospital, Stockholm, Sweden.

6) From the protocols of Nico Pijls, MD, Catharina Hospital, The Eindhoven, NL and Istvan Herzfeld, MD, Stockholm South Hospital, Sweden.

7) R Wilson et al.
Effects of Adenosine on Human Coronary Arterial Circulation
Circulation. 1990;82:1595-1606.

8) N Pijls et al.
Practice and potential pitfalls of coronary pressure measurement
Catheter Cardiovasc Interv. 2000;49:17-18.

Intravenous Adenosine


- Administered through the **femoral vein** or a large **cubital vein** the usual dose in clinical practice is 140 µg/kg/min
- Peak effect in around 1 min. Effect wears off 1 min after the infusion is stopped.
- FFR measurement of 0.75–0.80 the dose of the IV infusion can be safely increased to 180 µg/kg/min

Intravenous Adenosine

- AV block less common - Can provoke bronchoconstriction – not for asthma or COPD
- **Unpleasant angina like sensation** – NOT harmful – informed patient prevents undue alarm
- Sensation passes quickly after ending the infusion If asymptomatic patient – drug administered correctly?
- Decrease of BP (10 – 20 %) similar increase of the Heart Rate

Intravenous Adenosine


- High infusion rate pump
- If brachial vein – arm extended
- Nitrates
- Steady state hyperemia, allows pullback curve to be recorded (for serial stenosis)
- Short half life – avoid valsalva maneuver (no interruption of venous return) – fluctuation of Pd/Pa curve
- Breath normally



Preparation

Preparation of Intravenous Adenosine

1. Remove 40 ml from a 100 ml bag of iv saline and discard.
2. Draw up 30 ml (90 mg) of adenosine (3 mg/ml; either 15 × 2ml vials or 3 × 10 ml vials).
3. Add adenosine to the 60 ml iv saline giving a concentration of 1 mg/ml.



Ex: 90 mg (30 ml) = 90mg/30 + 60 ml = 1mg/ml

Patient 75kg → 630 mg/h → 10,5 mg/min = 10,5 ml/min →

Procedure: 2,5 min/ vessel (incl inf - peak) = 7,5 min → ~ 80 ml

Dosage Chart

TABLE I. Dosage Table for IV Adenosine at 140 µg/kg/min

| Weight (lb) | Weight (kg) | Infusion (ml/hr) |
|-------------|-------------|------------------|
| 99 | 45 | 378 |
| 110 | 50 | 420 |
| 121 | 55 | 462 |
| 132 | 60 | 504 |
| 143 | 65 | 546 |
| 154 | 70 | 588 |
| 165 | 75 | 630 |
| 176 | 80 | 672 |
| 187 | 85 | 714 |
| 198 | 90 | 756 |
| 209 | 95 | 798 |
| 220 | 100 | 840 |
| 231 | 105 | 882 |
| 243 | 110 | 924 |
| 254 | 115 | 966 |
| 265 | 120 | 1008 |



When IV Adenosine?

- Serial lesions
- Diffuse disease
- Stent assessment


When IC Adenosine?

- Single lesions
- Patients with asthma




Regadenoson

- Εκλεκτικός A_{2A} Αγωνιστής
- Ύπεραυμία ~2-5 λεπτά
- Χορήγησε σε μια δόση



Quantitative Coronary Angiography (QCA)

Edge detection




Δεν είναι ακριβώς
λειτουργική δοκιμασία

Δε χρησιμοποιούμε
υπεραιμία


Οπτική επιθεώρηση
του διαγράμματος του
αυλού από το
σκιαγραφικό

Πλεονέκτημα:
Ελευθερία από
σφάλμα παρατηρητή
(intraobserver and
interobserver
variability)


Quantitative Coronary Angiography





PITFALL : LESION ECCENTRICITY



PITFALL : LESION ECCENTRICITY




Two examples of angiograms difficult to evaluate by quantitative angiography.




Topol E J , and Nissen S E *Circulation*. 1995;92:2333-2342

Angiographic underestimation of CAD

Diffuse disease




Luminology




Schematic representation of an important limitation of projection imaging.

A



B



Fractional Flow Reserve (FFR)


$$FFR = \frac{\text{Distal Coronary Pressure}}{\text{Proximal Coronary Pressure}}$$

(During Maximum Hyperemia)

Measure post intra -coronary Adenosine

No flow obstruction FFR > 0.8

Flow obstruction FFR < 0.75



FFR

Fractional flow reserve (FFR) is the ratio of hyperemic myocardial flow in the stenotic territory (Q_s^{\max}) to normal hyperemic myocardial flow (Q_N^{\max})

$$FFR = \frac{Q_s^{\max}}{Q_N^{\max}}$$

FFR

Since the flow (Q) is the ratio of the pressure (P) difference across the coronary system divided by its resistance (R), Q can be substituted as follows:

$$\text{FFR} = \frac{(P_d - P_v)/R_s^{\max}}{(P_a - P_v)/R_N^{\max}}$$

FFR




Since the measurements are obtained under maximal hyperemia, resistances are minimal and therefore equal, and thus they cancel out:

$$\text{FFR} = \frac{(P_d - P_v)}{(P_a - P_v)}$$

FFR

In addition P_v is negligible as compared to P_a or P_d , therefore:

$$FFR = \frac{P_d}{P_a}$$




$$FFR = \frac{P_d - P_v}{P_a - P_v} \approx \frac{P_d}{P_a}$$

Analyzer for FFR?

PressureWire® is attached to an Analyzer (console), an interface which makes the FFR calculations automatically during the procedure.

It displays both aortic and distal pressure wave forms.




FFR

Pressure Wire – 0.014 hollow wire

Shape tip and use like a normal work horse wire for ptca/stent




The Meaning of an FFR Value



ΦΥΣΙΟΛΟΓΙΚΗ ΤΙΜΗ FFR 1


Όσο χαμηλότερη είναι η τιμή του FFR τόσο χαμηλότερη η ροή στο μυοκάρδιο (γραμμική συσχέτιση)

FFR >0.8 Φυσιολογικό
FFR <0.75 Παθολογικό
0.75<FFR<0.8 Γκρίζα ζώνη
(χρειάζεται περισσότερη υπεραιμία)







How Accurate is the Value?




FFR < 0.75 : Sensitivity = 88%
Specificity = 100%






FFR has been validated against a “gold standard” of reversible ischemia, composed of all non-invasive tests.

Pijls NHJ et al.
N Eng J Med. 1996;334(no26): 1703-08.







FFR STUDIES

1. DEFER


2. FAME

3. FAME 2

DEFER STUDY (2007)

- RCT
- 325 PATIENTS with functionally not significant stenosis (i.e. without ischemia)
- According to the study protocol:
 - If FFR < 0.75: PCI performed
 - If FFR > 0.75: randomization DEFER or PCI
- 50% of patients with intermediate lesions do not need intervention and will not benefit from it

FAME 1 Trial (2009)



The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

JANUARY 15, 2009

VOL. 360 NO. 3

Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Intervention

Pim A.L. Tonino, M.D., Bernard De Bruyne, M.D., Ph.D., Nico H.J. Pijls, M.D., Ph.D., Uwe Siebert, M.D., M.P.H., Sc.D., Fumiaki Ikeno, M.D., Marcel van 't Veer, M.Sc., Volker Klauss, M.D., Ph.D., Ganesh Manoharan, M.D., Thomas Engström, M.D., Ph.D., Keith G. Oldroyd, M.D., Peter N. Ver Lee, M.D., Philip A. MacCarthy, M.D., Ph.D., and William F. Fearon, M.D., for the FAME Study Investigators*

CONCLUSIONS

Routine measurement of FFR in patients with multivessel coronary artery disease who are undergoing PCI with drug-eluting stents significantly reduces the rate of the composite end point of death, nonfatal myocardial infarction, and repeat revascularization at 1 year. (ClinicalTrials.gov number, NCT00267774.)

FAME 1 Trial




Figure 3. Kaplan-Meier Survival Curves According to Study Group.

FFR denotes fractional flow reserve, and PCI percutaneous coronary intervention.

Βελτιώνει MACE
Όχι επιβίωση!

FAME 2 Trial (2012)

The NEW ENGLAND JOURNAL of MEDICINE

ESTABLISHED IN 1812

SEPTEMBER 13, 2012

VOL. 367 NO. 11

Fractional Flow Reserve–Guided PCI versus Medical Therapy in Stable Coronary Disease

Bernard De Bruyne, M.D., Ph.D., Nico H.J. Pijls, M.D., Ph.D., Bindu Kalesan, M.P.H., Emanuele Barbato, M.D., Ph.D., Pim A.L. Tonino, M.D., Ph.D., Zsolt Piroth, M.D., Nikola Jagic, M.D., Sven Möbius-Winkler, M.D., Gilles Rioufol, M.D., Ph.D., Nils Witt, M.D., Ph.D., Petr Kala, M.D., Philip MacCarthy, M.D., Thomas Engström, M.D., Keith G. Oldroyd, M.D., Kreton Mavromatis, M.D., Ganesh Manoharan, M.D., Peter Verlee, M.D., Ole Frøbert, M.D., Nick Curzen, B.M., Ph.D., Jane B. Johnson, R.N., B.S.N., Peter Jüni, M.D., and William F. Fearon, M.D., for the FAME 2 Trial Investigators*

CONCLUSIONS

In patients with stable coronary artery disease and functionally significant stenoses, FFR-guided PCI plus the best available medical therapy, as compared with the best available medical therapy alone, decreased the need for urgent revascularization. In patients without ischemia, the outcome appeared to be favorable with the best available medical therapy alone. (Funded by St. Jude Medical; ClinicalTrials.gov number, NCT01132495.)

FAME 2 Trial




Figure 1. Cumulative Incidence of the Primary End Point and Its Components.

FFR doesn't just improve health outcomes, it decreases costs

- FAME 1 showed that FFR both improves patient outcome and lowers procedural costs – FFR is cost-saving when used to guide PCI in MVD.
- FAME 2 demonstrated that angina and quality of life are significantly improved by FFR-guided PCI as compared to OMT and that FFR-guided PCI is cost-effective with ICER \$32,000/QALY.

| STUDY | COMPARATORS | COST-EFFECTIVENESS RATIO | RESULT |
|---------|-------------------------------------|--|-------------------|
| COURAGE | Angio-guided PCI vs Medical Therapy | >\$168,000 / QALY | >\$150,000 / QALY |
| FAME | Angio-guided PCI vs FFR-guided PCI | FFR-guided PCI is Dominant (↓\$/↑QALY) | <\$50,000 / QALY |
| FAME 2 | FFR-guided PCI vs Medical Therapy | \$32,000 / QALY | <\$50,000 / QALY |



The legend defines three categories based on the Cost-Effectiveness Ratio (ICER):

- Very Cost-Effective:** <\$50,000 / QALY (represented by a teal square)
- Cost-Effective:** \$50,000-150,000 / QALY (represented by a yellow square)
- Not Cost-Effective:** >\$150,000 / QALY (represented by a dark gray/black square)

* A utility is a numeric way of expressing of a patient's preference for a particular state of health; a higher value equals improved health (typically, 0.0=dead; 1.0=complete health).

FFR doesn't just improve health outcomes, it decreases costs

Methods and results

- Initial costs of the index hospitalization were \$6,026 higher for PCI, but over the course of 1 year, follow-up costs were higher for medical therapy, narrowing the gap to \$2,883.

| | PCI (n=447) | Medical Therapy (n=441) | P Value |
|-------------------------------|------------------------|--|----------------|
| Index Procedure | \$9,927 | \$3,900 | < 0.001 |
| Follow-up | \$2,719 | \$5,863 | < 0.001 |
| Total at 12 months | \$12,646 | \$9,763 | < 0.001 |

Recommendations for the clinical value of intracoronary diagnostic techniques

| Recommendations | Class ^a | Level ^b | Ref. ^c |
|--|--------------------|--------------------|-------------------|
| FFR to identify haemodynamically relevant coronary lesion(s) in stable patients when evidence of ischaemia is not available. | I | A | 50,51,713 |
| FFR-guided PCI in patients with multivessel disease. | IIa | B | 54 |
| IVUS in selected patients to optimize stent implantation. | IIa | B | 702,703,706 |
| IVUS to assess severity and optimize treatment of unprotected left main lesions. | IIa | B | 705 |
| IVUS or OCT to assess mechanisms of stent failure. | IIa | C | |
| OCT in selected patients to optimize stent implantation. | IIb | C | |

ESC Guidelines 2014
(Stable CAD)


Initial studies suggested that the cut-off figure of 0.75 was reliable for identifying ischaemia-producing lesions, but subsequently the 0.80 criterion has gained widespread acceptance and its clinical role has been validated in outcome studies.

Pitfalls & Practical Tips


- **Transducer Height and AO Pressure**
- Equalization
- Guide wire Introducer Needles
- Guide Catheter (wedging, damping & side holes)
- Pressure Wire™ Drift
- Artifacts
- Mean-beat Setting
- Sensor Element Against Vessel Wall
- **Suboptimal Hyperaemia**

Importance of Transducer Height and AO Pressure

Position the AO transducer at patient's heart level (midaxillary line)




Effect of Moving the Aortic Transducer




Pitfalls & Practical Tips

- Transducer Height and AO Pressure
- **Equalization**
- Guide Wire Introducer Needles
- Guide Catheter (wedging, damping & side holes)
- Pressure Wire Drift
- Artifacts
- Mean-beat Setting
- Sensor Element Against Vessel Wall
- Suboptimal Hyperaemia

Equalization



PressureWire sensor just outside tip of guide catheter




Equalization between the aortic pressure transducer and Pressure Wire sensor must always take place with PressureWire sensor just outside the tip of the guide catheter.

Pitfalls & Practical Tips


- Transducer Height and AO Pressure
- Equalization
- **Guidewire Introducer Needles**
- Guide Catheter (wedging, damping & side holes)
- PressureWire Drift
- Artifacts
- Mean-beat Setting
- Sensor Element Against Vessel Wall
- Suboptimal Hyperemia

Guidewire Introducer Needles




The introducer needle may leak blood and decrease aortic pressure (Pa) by 0–10 mmHg and result in a falsely high FFR.
More leakage from larger bore needles (shown in yellow) than small ones (clear).

Effect of Large Needle



In this example, using a large bore, the yellow needle causes a drop in aortic pressure of approximately 10 mmHg.

Effect of Thin Needle




In this case, the introducer needle has a small lumen, which creates minimal pressure leakage.

Pitfalls & Practical Tips

- Transducer Height and AO Pressure
- Equalization
- Guide Wire Introducer Needles
- **Guide Catheter (wedging, damping & side holes)**
- Pressure Wire Drift
- Artifacts
- Mean-beat Setting
- Sensor Element Against Vessel Wall
- Suboptimal Hyperaemia



Wedging of Guide Catheter



The presence of a guide catheter in the coronary ostium induces some degree of “stenosis” depending on the relative size of the guide and the coronary ostium.


Pa value falsely low and FFR falsely high.

Deep-Seated (Wedged) Guide Catheter




A deep-seated (wedged) guide catheter in the ostium of the right or left main vessels can cause damping of the aortic waveform. Waveform 1 shows the effect with the catheter inserted and waveform 2 shows the effect when the catheter is withdrawn into the aorta, revealing an immediate pressure gradient.

Guide Catheter in Ostium = Stenosis



This is a schematic representation of the space occupied by different sizes of guide catheters in an ostium 3 mm in diameter (radius = 1.5 mm).

Effect of Guide Catheter with Side Holes




If a guide catheter with side holes is used, the pressure signal recorded through the catheter does not necessarily correspond to the pressure in the proximal segment of the coronary artery since it is influenced by both coronary pressure (through the distal end of the catheter) and by aortic pressure (through the side holes).

Pitfalls & Practical Tips

- Transducer Height and AO Pressure
- Equalization
- Guidewire Introducer Needles
- Guide Catheter (wedging, damping & side holes)
- **PressureWire Drift**
- Artifacts
- Mean-beat Setting
- Sensor Element Against Vessel Wall
- Suboptimal Hyperemia

Drift Waveform

Drift



After a long procedure, differences may sometimes occur between aortic and distal pressures even if this difference does not correspond to a true pressure gradient.

Pitfalls & Practical Tips

- Transducer Height and AO Pressure
- Equalization
- Guidewire Introducer Needles
- Guide Catheter (wedging, damping & side holes)
- PressureWire Drift
- **Artifacts**
- Mean-beat Setting
- Sensor Element Against Vessel Wall
- Suboptimal Hyperemia

Flush Artifact




RadiAnalyzer Xpress selects artifact



Actual FFR is 0.83

Blunted Flush Artifact

No red phasic signal but mean signal remains



One-Beat Artifact



Pitfalls & Practical Tips

- Transducer Height and AO Pressure
- Equalization
- Guidewire Introducer Needles
- Guide Catheter (wedging, damping & side holes)
- PressureWire Drift
- Artifacts
- Mean-beat Setting
- Sensor Element Against Vessel Wall
- **Suboptimal Hyperemia**

Suboptimal Maximal Hyperaemia



Fluctuating Pd/Pa line = steady state
NOT achieved and likely sub-optimal maximal hyperaemia

Steady-State Maximal Hyperaemia



steady state

Practical Aspects of LM FFR:



- First measure FFR in the least diseased vessel, preferably the LAD, with a pullback
 - If FFR < 0.80, then revascularize
 - If FFR > 0.85, then treat medically
 - If FFR between 0.80 and 0.85 and there is significant downstream epicardial disease in the other epicardial vessel, then can consider IVUS

Practical Aspects of LM FFR:

- Intravenous adenosine is the ideal hyperemic agent because it allows time to pull the guide catheter out of the ostium.
- A physiologic evaluation of left main disease, compared to an anatomic evaluation alone, is safe and appropriate, just as it is in non-left main CAD.
- Never forget the patient and the clinical scenario.

Effect of Epicardial Lesions on FFR Assessment of Intermediate LM Disease

Animal Model



$$\text{FFR}_{\text{true}} = 45/61 = 0.74$$

$$\text{FFR}_{\text{app}} = 47/61 = 0.77$$


$$\text{FFR}_{\text{epicardial}} = 40/61 = 0.66$$

F


Left Main Stem Stenoses are Rarely Isolated

The influence of a distal stenosis on the FFR of the LM depends on the extent to which hyperemic flow across the LM stenosis will be decreased by this distal lesion

- Severity
- Myocardial mass



Effect of Tandem Lesions



FFR KAI PCI

FFR CUT-OFF μετά από αγγειοπλαστική είναι το
0.9, όχι 0.8

- **ΜΟΝΟ ΜΙΑ ΜΙΚΡΗ ΜΕΛΕΤΗ**


FFR KAI CABG

Ασθενείς με ενδιάμεσες στενώσεις (όχι LM)

- GROUP 1 ($\Sigma/\Phi \Rightarrow$ CABG)
- GROUP 2 (FFR \Rightarrow CABG)
- **FFR CUT-OFF \Rightarrow 0.8**


GROUP 2 \Rightarrow

- \downarrow αριθμός μοσχευμάτων
- \downarrow on-pump χειρουργείο
- \downarrow μετεγχειρητική στηθάγχη



Off-pump Coronary Artery Bypass (OPCAB)

FFR KAI nSTEMI



ΥΠΑΡΧΕΙ ΜΟΝΟ ΜΙΑ ΜΕΛΕΘΗ
(FAMOUS – NSTEMI)

CONCLUSION:

In NSTEMI patients, angiography-guided management was associated with higher rates of coronary revascularization compared with FFR-guided management. A larger trial is necessary to assess health outcomes and cost-effectiveness.

Instantaneous wave free ratio (iFR)


- iFR isolates a **specific period in diastole**, called the wave-free period, and uses the ratio of distal coronary pressure (Pd) to the pressure observed in the aorta (Pa) over this period.
- When stenoses are flow limiting, Pd and Pa pressures over the wave-free period diverge; a normal ratio is 1.0 and iFR values of below 0.90 suggest flow limitation.
- iFR can be calculated using dedicated consoles available for medical use and typically uses an average over 5 heart beats but can be performed **using a single heart beat**.
- iFR is measured at rest, without the need for pharmacological vasodilators or stressors and compares well to other invasive and non-invasive markers of ischemia or flow limitation.

Instantaneous wave free ratio (iFR)

- iFR vs FFR
- Δε χρειάζεται υπεραιμία!
 - FFR => Μέση πίεση άπω της στένωσης => Σε όλη τη διάρκεια του κύκλου => Μέγιστη υπεραιμία
 - iFR => Μέτρηση πίεσης εγγύς και άπω της βλάβης από το 25% της διαστολικής φάσης => έως την τελοδιαστολή


iFR

IFR = Pd/Pa
No adenosine






ΜΕΛΕΤΕΣ iFR

- ADVISE
- CLARIFY
- VERIFY



ADVISE STUDY=establishment



Journal of the American College of Cardiology
Volume 59, Issue 15, 10 April 2012, Pages 1392-1402





Focus Issue: Transcatheter Cardiovascular Therapeutics
Coronary Disease

Development and Validation of a New Adenosine-Independent Index of Stenosis Severity From Coronary Wave-Intensity Analysis: Results of the ADVISE (ADenosine Vasodilator Independent Stenosis Evaluation) Study

Sayan Sen MBBS * Javier Escaned MD, PhD †, Iqbal S. Malik MBBS, PhD ‡, Ghada W. Mikhail MBBS, MD ‡, Rodney A. Foale MD †, Rafael Mila MD †, Jason Tarkin MBBS †, Ricardo Petaco MD †, Christopher Brody MBBS †, Richard Jabbour MBBS †, Amarjit Sethi MBBS, PhD ‡, Christopher S. Baker MBBS, PhD ‡, Michael Bellamy MBBS, MD ‡, Mahmud Al-Bustami MD ‡, David Hackett MD ‡, Masood Khan MB, BChir, MA ‡, David Lefroy MB, BChir, MA ‡, Kim H. Parker PhD § ... Justin E. Davies MBBS, PhD *


CLARIFY STUDY



CONCLUSIONS:

iFR and FFR had equivalent agreement with classification of coronary stenosis severity by HSR. Further reduction in resistance by the administration of adenosine did not improve diagnostic categorization, indicating that iFR can be used as an adenosine-free alternative to FFR.

VERIFY STUDY



CONCLUSIONS:

iFR correlates **weakly** with FFR and **is not independent of hyperemia**. iFR **cannot be recommended** for clinical decision making in patients with coronary artery disease.

VIRTUAL FFR

- Επεξεργασία και
- 3D απεικόνιση δεδομένων από Σ/Φ
- Computational fluid dynamics remodelling
- ΜΕΛΑETH VIRTU -1

JACC: CARDIOVASCULAR INTERVENTIONS
© 2015 BY THE AMERICAN COLLEGE OF CARDIOLOGY FOUNDATION
PUBLISHED BY ELSEVIER INC.

VOL. 8, NO. 8, 2015
ISSN 1936-8798/\$36.00
<http://dx.doi.org/10.1016/j.jcin.2015.04.006>

VIEWPOINT

INTERVENTIONAL ISSUES

“Virtual” (Computed) Fractional Flow Reserve

Current Challenges and Limitations

Paul D. Morris, MBCnB,*† Frans N. van de Vosse, PhD,‡ Patricia V. Lawford, PhD,* D. Rodney Hose, PhD,* Julian P. Gunn, MD*†



ΜΕΛΕΤΗ VIRTU -1

- 35 Στεφανιαίες στενώσεις – 22 αγγεία
- Κάθετες λήψεις (τουλάχιστον 35° μεταξύ τους)
- Μέγιστη υπεραιμία με αδενοσίνη
- vFFR => FFR ± 0.06
- Ειδικό Software => 24h Ανάλυση Δεδομένων

ΜΕΛΕΤΗ VIRTU -1

